Abstract. Hypoxia occurs frequently in various solid tumors and elicits a cellular response designed to improve cell survival through adaptive processes, thereby accelerating cancer progression and the development of chemotherapy resistance. Tumor necrosis factor-related apoptosis-inducing ligand (Trail), a member of the TnF superfamily, leads to tumor cell death via both intrinsic and extrinsic apoptotic signaling pathways. Hypoxia inhibits Trail-mediated apoptosis and attenuates the therapeutic activity of Trail in cancer management. Hypoxia-inducible factor-1α (HiF-1α) plays a central role in tumor hypoxia by up-regulating gene expression related to angiogenesis, cancer invasion and antiapoptosis. Sulforaphane (SFn), a phenethyl isothiocyanate, elicits HiF-1α inactivation under hypoxia. This study investigated whether hypoxic inhibition of Trail-mediated tumor cell death is increased by SFn-mediated HiF-1α instability. SFn induced cell death in various tumor cells, including SK-n-SH, Snu-638, Hela and a549 cells, and showed cell cytotoxicity in hypoxia-exposed tumor cells. Western blot analysis showed that SFn treatment increased p53 and activated caspase-3 proteins, and decreased HiF-1α activation under hypoxia. under low-oxygen conditions, Trail-treated cells displayed inhibited apoptosis, while SFn-pre-treated cells exhibited stronger sensitization to Trail under the hypoxic conditions. SFn treatment enhanced Trail-induced activation of proteins, including caspase-3 and p53. SFn dosedependently decreased HiF-1α protein levels in cancer cells, which was mediated by decreased protein stability. This study demonstrated that SFn recovered hypoxia-mediated resistance to Trail via instability of HiF-1α, and also suggests that combination therapy with SFn and Trail may provide a novel strategy for treating hypoxic solid tumors.